IVERIC bio (ISEE) Peer Comparison

$39.95

$0.00 (0.00%)

As on 11-Jul-2023 09:30EDT

Market cap

$5,512 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

3.8

Div. Yield

0 %

Edit

	IVERIC bio (ISEE)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
Market cap ($ Mln)	5,512	16,765	13,492	11,994	11,957
Revenue ($ Mln)	--	2,782	2,436	670	1,664
Net Profit ($ Mln)	-212.14	491.50	860.62	-319.95	413.60
Net Margin (%)	-36,512.56	17.67	35.33	-47.79	24.86
RoE (%)	-57.58	110.09	42.98	-71.14	430.03
Price to Earnings	--	35.25	17.40	--	30.89
Price-To-Book	3.81	39.29	7.42	26.87	84.52

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	IVERIC bio (ISEE)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
Operating Revenue	0.00	1,460.00	1,611.06	243.23	660.12
Cost of Revenue	0.00	1,027.56	57.91	10.42	139.30
Gross Profit	--	432.44	1,553.15	243.23	520.81
Operating Expenses	229.08	153.74	1,351.67	421.74	253.28
Operating Profit (EBIT)	-229.08	278.70	201.48	-178.51	267.53
Other Income	0.58	7.07	-0.20	0.77	-1.67
Profit before Tax	-222.90	282.86	234.35	-172.71	248.92
Provision for Tax	-10.77	37.49	52.07	3.79	46.79
Profit after Tax (Net Income)	-212.14	245.37	182.28	-176.49	202.13
Minority Interest	0.00	--	--	19.82	--
Consolidated Profit	-222.90	245.37	182.28	-176.06	202.13

Liabilities ($ Mln)

	IVERIC bio (ISEE)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
Shareholder's Funds	477.05	386.39	2,488.43	398.52	169.80
Minority Interest	0.00	--	--	19.82	--
Non-Current Liabilities	96.99	162.64	258.70	134.75	1,540.92
Current Liabilities	39.37	803.47	324.36	138.85	130.79
Total Liabilities	666.82	1,352.50	3,071.49	691.94	1,841.51

Assets ($ Mln)

	IVERIC bio (ISEE)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
Non-Current Assets	1.86	1,018.53	1,452.73	286.64	1,102.50
Current Assets	611.54	333.96	1,618.76	405.30	739.01
Total Assets	666.92	1,352.50	3,071.49	691.94	1,841.51
Total Debt*	97.76	188.87	190.17	81.58	1,506.10
Net Current Assets	572.17	-469.51	1,294.40	302.30	608.22

Cashflow ($ Mln)

	IVERIC bio (ISEE)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
Cash From Operating Activities	-163.77	388.05	362.61	-136.13	240.11
Cash Flow from Investing Activities	-50.28	-38.74	-524.41	-5.42	-487.01
Cash from Financing Activities	428.91	-775.78	0.59	65.19	362.37
Net Cash Inflow / Outflow	214.86	-426.47	-161.21	-76.36	115.48

Ratios

Profitability Ratios

	IVERIC bio (ISEE)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
ROCE (%)	-35.34	29.58	7.38	-38.60	14.70
ROE (%)	-57.58	36.64	7.76	-43.72	110.23
ROA (%)	-41.41	16.29	6.41	-25.18	13.72
EBIT Margin (%)	--	--	--	--	--
Net Margin (%)	-36,512.56	16.73	11.32	-72.33	30.70
Cash Profit Margin (%)	--	--	--	--	--

Growth Ratios

	IVERIC bio (ISEE)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
Revenue Growth (%)	--	0.28	0.12	0.76	0.49
EBIT Growth (%)	-87.19	--	--	--	--
Net Profit Growth (%)	-73.89	34.93	-21.11	-25.31	-49.81
EPS Growth (%)	-48.14	0.57	-0.21	-0.24	-0.48
Book Value Growth (%)	24.04	--	--	--	--

Valuation Ratios

	IVERIC bio (ISEE)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
Price / Earnings	-15.27	28.07	28.45	-19.80	39.02
Price / Book Value	5.02	17.82	2.08	8.77	46.45
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	-11.10	22.87	18.29	-19.04	28.62
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	IVERIC bio (ISEE)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
Debt to Equity	0.20	0.49	0.08	0.20	8.87
Short term debt to equity ratio	0.00	0.13	0.01	0.01	0.08
Current Ratio	15.53	0.42	4.99	2.92	5.65
Quick Ratio	15.53	--	4.89	3.07	4.88
Interest Coverage	-58.55	98.37	3.75	-35.47	15.69

Operating Efficiency Ratios

	IVERIC bio (ISEE)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
Debtors to sales (%)	--	17.36	13.33	0.58	35.00
Asset Turnover	0.00	0.97	0.57	0.35	0.45
Receivable days	--	55.02	56.39	8.76	89.10
Inventory Days	--	--	191.72	-302.34	201.93
Payable days	--	10.44	179.52	215.99	25.22
Cash Conversion Cycle	--	--	68.58	-509.57	265.81

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly